Feed ANUHPHR.NS
Summary
64 / 100 · Bulios Score
Valuation 67Growth 67Profitability 21Quality 67Debt 100Stability 66
What speaks for it
- It holds more cash than debt: ₹83.0M against ₹583.0K.
- Revenue grew by 14% a year over the last 3 years.
What to watch
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapP/E against the industry (Drug Manufacturers - Specialty & Generic)
P/E today 20.1 Industry median 39.6
Today you pay 20.1 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (INR)
20212022202320242025
Diluted EPS (INR)
20212022202320242025
Revenue grew by 14% a year over the last 3 years. Earnings per share grew by 4.3% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 INR of revenue goes
- Cost of sales 80 INR
- Sales and administration 13 INR
- Taxes and other 1.2 INR
- Net profit 5.7 INR
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 21 INR
Out of every 100 INR of revenue, 5.7 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesCash and short-term investments ₹531.6M
Debt ₹583.0K
It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.82%
- Paid out of profit
- 37%
You receive ₹1.50 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail